{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:24:14Z","timestamp":1788542654597,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The effect of various reduced doses of verteporfin photodynamic therapy (PDT) on choroidal blood flow in chronic central serous chorioretinopathy (CSC) remains unclear. Therefore, this study aimed to evaluate choroidal blood flow after half-dose PDT (1\/2PDT) and one-third dose PDT (1\/3PDT) with verteporfin for chronic CSC using laser speckle flowgraphy and spectral-domain optical coherence tomography.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-seven eyes of 27 patients with serous retinal detachment (SRD) caused by chronic CSC for more than 6\u2009months were included in this study. Patients were divided into the 1\/2PDT (<jats:italic>n<\/jats:italic>\u2009=\u200912; January 2018 to July 2019) and 1\/3PDT (<jats:italic>n<\/jats:italic>\u2009=\u200915; August 2016 to December 2017) groups based on the treatment period. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), central choroidal thickness (CCT), and mean blur rate in the macular area (m-MBR) and optic nerve head (ONH-MBR) were obtained using laser speckle flowgraphy and evaluated at baseline (pre-treatment), and 2\u2009weeks, 1\u2009month, 3\u2009months, and 6\u2009months after treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that SRD disappeared after 1\u2009month in 92 and 93% of patients\u2019 eyes in the 1\/2PDT and 1\/3PDT groups, respectively. Recurrence of SRD was observed in one eye at the 6-month follow-up after 1\/2PDT and two eyes at the 3-month follow-up after 1\/3PDT. No significant improvement was observed in baseline BCVA in the 1\/3PDT and 1\/2PDT groups. The average m-MBR against baseline significantly decreased at 2\u2009weeks and 1, 3, and 6\u2009months in the 1\/2PDT group. The average m-MBR against baseline decreased significantly only at the 2\u2009weeks follow-up in the 1\/3PDT group. The average rate of change in the CCT against baseline decreased significantly throughout for up to 6\u2009months in the 1\/2PDT group and for up to 3\u2009months in the 1\/3PDT group. No significant fluctuation was observed in the ONH-MBR.<\/jats:p>\n                <jats:p>Conclusions: Here, PDT significantly affected choroidal blood flow depending on the verteporfin dose in chronic CSC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial was retrospectively registered (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/upload.umin.ac.jp\/rd\/rd.cgi?t=ic&amp;n=R000030814&amp;k=1004U3r4nesmqJlV1x2HL75O\">UMIN000026850<\/jats:ext-link>; Approval date 03\/04\/2017).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-021-01980-w","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T01:02:21Z","timestamp":1622422941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy"],"prefix":"10.1186","volume":"21","author":[{"given":"Shun","family":"Kumashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"issue":"2","key":"1980_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","volume":"29","author":"DL Nickla","year":"2010","unstructured":"Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010;29(2):144\u201368. https:\/\/doi.org\/10.1016\/j.preteyeres.2009.12.002.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"1980_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000085728","volume":"219","author":"F Afrashi","year":"2005","unstructured":"Afrashi F, Erakgun T, Uzunel D, Mentes J, Kose S, Akkin C. Comparison of achromatic and blue-on-yellow perimetry in patients with resolved central serous chorioretinopathy. Ophthalmologica. 2005;219(4):202\u20135. https:\/\/doi.org\/10.1159\/000085728.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1980_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajo.2009.01.018","volume":"148","author":"H Matsumoto","year":"2009","unstructured":"Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol. 2009;148(1):105\u201310.e1.","journal-title":"Am J Ophthalmol"},{"key":"1980_CR4","first-page":"T8","volume":"113","author":"TY Lai","year":"2015","unstructured":"Lai TY, Wong RL, Chan WM. Long-term outcome of half-dose Verteporfin photodynamic therapy for the treatment of central serous Chorioretinopathy (an American ophthalmological society thesis). Trans Am Ophthalmol Soc. 2015;113:T8.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"2","key":"1980_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/ojo.OJO_75_2017","volume":"11","author":"GJ Manayath","year":"2018","unstructured":"Manayath GJ, Ranjan R, Shah VS, Karandikar SS, Saravanan VR, Narendran V. Central serous chorioretinopathy: current update on pathophysiology and multimodal imaging. Oman J Ophthalmol. 2018;11(2):103\u201312. https:\/\/doi.org\/10.4103\/ojo.OJO_75_2017.","journal-title":"Oman J Ophthalmol"},{"key":"1980_CR6","unstructured":"Gass J. Stereoscopic Atlas of Macular Diseases. 4th ed. St Louis; 1997. p. 49Y70."},{"issue":"9","key":"1980_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/bjophthalmol-2017-311338","volume":"102","author":"DS Maltsev","year":"2018","unstructured":"Maltsev DS, Kulikov AN, Chhablani J. Topography-guided identification of leakage point in central serous chorioretinopathy: a base for fluorescein angiography-free focal laser photocoagulation. Br J Ophthalmol. 2018;102(9):1218\u201325. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311338.","journal-title":"Br J Ophthalmol"},{"key":"1980_CR8","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003.","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"1980_CR9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1136\/bjo.87.12.1453","volume":"87","author":"WM Chan","year":"2003","unstructured":"Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453\u20138. https:\/\/doi.org\/10.1136\/bjo.87.12.1453.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1980_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00006982-200602000-00027","volume":"26","author":"M Colucciello","year":"2006","unstructured":"Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina. 2006;26(2):239\u201342.","journal-title":"Retina"},{"issue":"1","key":"1980_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10384-008-0613-z","volume":"53","author":"PY Lee","year":"2009","unstructured":"Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2009;53(1):52\u20136. https:\/\/doi.org\/10.1007\/s10384-008-0613-z.","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"1980_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ajo.2006.04.028","volume":"142","author":"V Isola","year":"2006","unstructured":"Isola V, Pece A, Parodi MB. Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol. 2006;142(4):680\u20133. https:\/\/doi.org\/10.1016\/j.ajo.2006.04.028.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"1980_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous Chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125(10):1547\u201355. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.021.","journal-title":"Ophthalmology"},{"issue":"3","key":"1980_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ophtha.2014.09.034","volume":"122","author":"K Fujita","year":"2015","unstructured":"Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, et al. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2015;122(3):555\u201361. https:\/\/doi.org\/10.1016\/j.ophtha.2014.09.034.","journal-title":"Ophthalmology"},{"issue":"3","key":"1980_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jamaophthalmol.2014.5312","volume":"133","author":"M Zhao","year":"2015","unstructured":"Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, et al. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333\u201340. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5312.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"1980_CR16","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1167\/iovs.15-17246","volume":"56","author":"M Saito","year":"2015","unstructured":"Saito M, Saito W, Hirooka K, Hashimoto Y, Mori S, Noda K, et al. Pulse waveform changes in macular choroidal hemodynamics with regression of acute central serous Chorioretinopathy. Invest Ophthalmol Vis Sci. 2015;56(11):6515\u201322. https:\/\/doi.org\/10.1167\/iovs.15-17246.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1980_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/bjophthalmol-2012-302349","volume":"97","author":"M Saito","year":"2013","unstructured":"Saito M, Saito W, Hashimoto Y, Yoshizawa C, Fujiya A, Noda K, et al. Macular choroidal blood flow velocity decreases with regression of acute central serous chorioretinopathy. Br J Ophthalmol. 2013;97(6):775\u201380. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302349.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"1980_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00417-012-1952-5","volume":"250","author":"T Shiba","year":"2012","unstructured":"Shiba T, Takahashi M, Hori Y, Maeno T. Pulse-wave analysis of optic nerve head circulation is significantly correlated with brachial-ankle pulse-wave velocity, carotid intima-media thickness, and age. Graefe's Arch Clin Exp Ophthalmol. 2012;250(9):1275\u201381.","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1980_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3928\/23258160-20150101-04","volume":"46","author":"M Okamoto","year":"2015","unstructured":"Okamoto M, Matsuura T, Ogata N. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy. Ophthalmic Surg, Lasers Imaging Retina. 2015;46(1):25\u201332. https:\/\/doi.org\/10.3928\/23258160-20150101-04.","journal-title":"Ophthalmic Surg, Lasers Imaging Retina"},{"issue":"3","key":"1980_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00006982-199616030-00004","volume":"16","author":"RF Spaide","year":"1996","unstructured":"Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203\u201313.","journal-title":"Retina"},{"issue":"4","key":"1980_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00417-014-2927-5","volume":"253","author":"K Hirooka","year":"2015","unstructured":"Hirooka K, Saito W, Namba K, Takemoto Y, Mizuuchi K, Uno T, et al. Relationship between choroidal blood flow velocity and choroidal thickness during systemic corticosteroid therapy for Vogt-Koyanagi-Harada disease. Graefe's Arch Clin Exp Ophthalmol. 2015;253(4):609\u201317.","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"issue":"10","key":"1980_CR22","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00417-019-04426-8","volume":"257","author":"W Park","year":"2019","unstructured":"Park W, Kim M, Kim RY, Park YH. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. Graefe's Arch Clin Exp Ophthalmol. 2019;257(10):2155\u201361.","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"issue":"6","key":"1980_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/aos.13059","volume":"94","author":"MB Breukink","year":"2016","unstructured":"Breukink MB, Mohabati D, van Dijk EH, den Hollander AI, de Jong EK, Dijkman G, et al. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study. Acta Ophthalmol. 2016;94(6):565\u201372. https:\/\/doi.org\/10.1111\/aos.13059.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1980_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/2008-322X.180706","volume":"11","author":"M Naseripour","year":"2016","unstructured":"Naseripour M, Falavarjani KG, Sedaghat A, Moghaddam AK, Nasserisina S, Alemzadeh SA. Half-dose photodynamic therapy for chronic central serous Chorioretinopathy. J Ophthalmic Vis Res. 2016;11(1):66\u20139. https:\/\/doi.org\/10.4103\/2008-322X.180706.","journal-title":"J Ophthalmic Vis Res"},{"issue":"7","key":"1980_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1055\/s-0041-106194","volume":"233","author":"F H\u00f6hn","year":"2016","unstructured":"H\u00f6hn F, Kretz FT, Beger I, Koch F, Auffarth GU, Singh P, et al. Half-dose Verteporfin photodynamic therapy (hdPDT) in the treatment of central serous Chorioretinopathy. Kl Monatsbl Augenheilkund. 2016;233(7):860\u20133. https:\/\/doi.org\/10.1055\/s-0041-106194.","journal-title":"Kl Monatsbl Augenheilkund"},{"issue":"8","key":"1980_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/IAE.0b013e3181a6c028","volume":"29","author":"MW Zhao","year":"2009","unstructured":"Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, et al. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina. 2009;29(8):1155\u201361.","journal-title":"Retina"},{"issue":"5","key":"1980_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/eye.2012.66","volume":"26","author":"R Uetani","year":"2012","unstructured":"Uetani R, Ito Y, Oiwa K, Ishikawa K, Terasaki H. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond). 2012;26(5):640\u20139.","journal-title":"Eye (Lond)"},{"issue":"10","key":"1980_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4103\/0301-4738.194999","volume":"64","author":"S Arora","year":"2016","unstructured":"Arora S, Pyare R, Sridharan P, Arora T, Thakar M, Ghosh B. Choroidal thickness evaluation of healthy eyes, central serous chorioretinopathy, and fellow eyes using spectral domain optical coherence tomography in Indian population. Indian J Ophthalmol. 2016;64(10):747\u201351. https:\/\/doi.org\/10.4103\/0301-4738.194999.","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"1980_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1471-2415-14-145","volume":"14","author":"F Hamzah","year":"2014","unstructured":"Hamzah F, Shinojima A, Mori R, Yuzawa M. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy. BMC Ophthalmol. 2014;14(1):145. https:\/\/doi.org\/10.1186\/1471-2415-14-145.","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"1980_CR30","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1097\/IAE.0000000000000998","volume":"36","author":"YR Chung","year":"2016","unstructured":"Chung YR, Kim JW, Kim SW, Lee K. CHOROIDAL THICKNESS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY: Assessment of Haller and Sattler Layers. Retina. 2016;36(9):1652\u20137.","journal-title":"Retina"},{"issue":"9","key":"1980_CR31","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1097\/IAE.0b013e31822bf6b1","volume":"31","author":"I Maruko","year":"2011","unstructured":"Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina. 2011;31(9):1921\u20137.","journal-title":"Retina"},{"issue":"9","key":"1980_CR32","doi-asserted-by":"publisher","first-page":"e0163104","DOI":"10.1371\/journal.pone.0163104","volume":"11","author":"T Kinoshita","year":"2016","unstructured":"Kinoshita T, Mitamura Y, Mori T, Akaiwa K, Semba K, Egawa M, et al. Changes in choroidal structures in eyes with chronic central serous Chorioretinopathy after half-dose photodynamic therapy. PLoS One. 2016;11(9):e0163104. https:\/\/doi.org\/10.1371\/journal.pone.0163104.","journal-title":"PLoS One"},{"issue":"4","key":"1980_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/bjophthalmol-2016-308921","volume":"101","author":"T Izumi","year":"2017","unstructured":"Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, et al. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol. 2017;101(4):433\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308921.","journal-title":"Br J Ophthalmol"},{"key":"1980_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ajo.2020.04.022","volume":"217","author":"C Iovino","year":"2020","unstructured":"Iovino C, Au A, Chhablani J, Parameswarappa DC, Rasheed MA, Cennamo G, et al. Choroidal anatomic alterations after photodynamic therapy for chronic central serous Chorioretinopathy: a multicenter study. Am J Ophthalmol. 2020;217:104\u201313. https:\/\/doi.org\/10.1016\/j.ajo.2020.04.022.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1980_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/ceo.12143","volume":"42","author":"M Saito","year":"2014","unstructured":"Saito M, Saito W, Hashimoto Y, Yoshizawa C, Shinmei Y, Noda K, et al. Correlation between decreased choroidal blood flow velocity and the pathogenesis of acute zonal occult outer retinopathy. Clin Exp Ophthalmol. 2014;42(2):139\u201350. https:\/\/doi.org\/10.1111\/ceo.12143.","journal-title":"Clin Exp Ophthalmol"},{"key":"1980_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/OPTH.S115685","volume":"11","author":"MB Breukink","year":"2017","unstructured":"Breukink MB, Dingemans AJ, den Hollander AI, Keunen JE, MacLaren RE, Fauser S, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin ophthalmol. 2017;11:39\u201346.","journal-title":"Clin ophthalmol"},{"issue":"4","key":"1980_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, et al. Long-term visual outcomes and causes of vision loss in chronic central serous Chorioretinopathy. Ophthalmology. 2019;126(4):576\u201388. https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.048.","journal-title":"Ophthalmology."},{"issue":"11","key":"1980_CR38","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/bjophthalmol-2018-313048","volume":"103","author":"NK Sahoo","year":"2019","unstructured":"Sahoo NK, Mishra SB, Iovino C, Singh SR, Munk MR, Berger L, et al. Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy. Br J Ophthalmol. 2019;103(11):1615\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313048.","journal-title":"Br J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-01980-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T01:02:25Z","timestamp":1622422945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-01980-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1980"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-01980-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was approved by the Ethics Committee of Toho University (#27\u2013277 Approval date 10\/3\/2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}